07-Oct-2019 - Evotec SE

Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc.

Aeovian and Evotec entered into a drug discovery partnership in 2017 to discover and develop new and highly selective mTORC1 inhibitors for the treatment of rare and age-related diseases. After nominating a pre-clinical development candidate within 18 months from starting the lead optimisation phase, Aeovian was recently able to successfully close a $ 37 m Series A financing round with lead investors venBio Partners and Sofinnova Investments and the participation of Apollo Health Ventures. Evotec received an undisclosed payment and has also participated in the financing round to secure additional upside from the further successful development of the jointly developed programme.

Evotec continues to support Aeovian’s project with the fully-integrated clinical-enabling service INDiGO as well as the process development for the production of the active pharmaceutical ingredient (“API”). The partners plan to work effectively towards submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”) and the initiation of clinical studies for Aeovian’s lead candidate.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “This milestone achievement with Aeovian is yet another impressive example of how Evotec’s integrated discovery and development platform contributes efficient execution to the medical innovation of its partners. The management of this chemically challenging project “under one roof” was key to delivering a PDC within 18 months from starting at the lead optimisation phase. We are confident that through our INDiGO and API manufacturing services we can continue to support the successful development of Aeovian’s project in the best way possible.”

Stelios T. Tzannis, PhD, President & CEO of Aeovian, added: “We are extremely glad about the fast progress of our programme which has been made possible by Evotec’s expertise and technical excellence. The successful identification and de-risking of our lead clinical candidate was instrumental in the closing of our Series A financing. We are excited to be working with our investors and the Evotec team towards the successful development of this innovative compound to bring relief to patients suffering from rare central nervous system (“CNS”) and age-related disorders.”

Facts, background information, dossiers
More about Evotec
  • News

    Evotec and Indivumed announce second joint drug discovery programme

    Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”). The final goal of this precision medicine collaboration is to deliver highl ... more

    Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome

    Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies ... more

    Evotec and Bristol-Myers Squibb expand iPSC collaboration

    Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 201 ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more